RAC 0.00% $1.61 race oncology ltd

Cardioprotection thread, page-599

  1. 1,014 Posts.
    lightbulb Created with Sketch. 11287
    Blimey, Rhino. You really want to see my mug again? Hah.

    If this post gets a substantial number of likes, I'll create a video addressing the following topics

    - rediscovered drugs
    -- the value of clinical history
    -- drive first-in-class products

    - bisantrene mechanisms of action
    -- the birth of two new drug classes
    -- the death of the anthracene model

    - FTO-inhibitor vs CPACS drugs
    -- what they do and why they are important
    -- how they are different
    -- clinical and commercial competition
    -- market size

    - literature supporting success and mitigating risk in proving CPACS in the clinic
    -- preclinical data
    -- clinical data
    (think of this like a systematic dot-connection to explain the clinical data for bisantrene with current understanding)

    - conceptualizing CPACS value on a global scale
    -- drivers of commercial success (boston research group)
    -- amalgamation of everything to synthesize the reality of a commercially viable, clinically proven first-in-class FTO-inhibitor and first-in-class CPACS drug

    I will ensure the quality and rigor is extensive. Done correctly, this will take a significant amount of my time. Please, only like this if you think it will provided substantial value to you and investors.
    Last edited by Mason14: 23/06/24
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
(20min delay)
Last
$1.61
Change
0.000(0.00%)
Mkt cap ! $273.4M
Open High Low Value Volume
$1.61 $1.66 $1.60 $207.2K 127.1K

Buyers (Bids)

No. Vol. Price($)
6 25510 $1.60
 

Sellers (Offers)

Price($) Vol. No.
$1.64 12000 1
View Market Depth
Last trade - 15.49pm 29/07/2024 (20 minute delay) ?
RAC (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.